Synonyms: 6,7-Dimethoxy-2-methyl-N-[(R)-1-(4-{2-[(methylamino)methyl]phenyl}thien-2-yl)ethyl]quinazolin-4-amine; BAY 293; BAY293
Molecular Formula: C25H28N4O2S
Molecular Weight: 448.58
Linear Structural Formula: C25H28N4O2S
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: BAY-293 selectively inhibits SOS1-mediated KRAS activation (IC50 = 52 nM; 50 nM wt or G12C hKRAS & 10 nM SOS1cat) via direct SOS1 binding, blocking SOS1-KRAS interaction (IC50 = 21 nM; 10 nM hSOS1cat & 5 nM hKRAS G12C) without affecting (IC50 >20 muM) CRAF RBD-KRAS interaction, KRAS G12C activation by SOS2, Cdc42 activation by DBS, or EGFR kinase activity. BAY-293 downregulates cellular active RAS (IC50 = 200 nM/Calu-1, 410 nM/HeLa) and downstream ERK phosphorylation (K-562, 150 nM/Calu-1) with good target selectivity as assessed over 358 kinases (<37 % inhibition at 1 mum) and a panel of 77 gpcrs, transporters, nuclear receptors and enzymes.<>